Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC
NCT05130684Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Feb 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05130684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130684.